Going forward..., page-2079

First 2079 Last

Share
Profile

Follow
Pledge

6,932 Posts.

1284

07/03/24

18:10

Post #: 72799752
Share

Originally posted by GH1971: ↑

Not saying it's easy, but the other MSC company has some very specific issues also. Leaving those aside, we do have the benefit of their experience and can learn from it. Walking in the footsteps of giants is a fairly sensible thing to do, if those footsteps lead into a minefield.

And given history I'd rather have Iqvia running our trials for us than CYP management doing it... They have much more experience and, one would hope, competence at it.

With respect to costs on the trial, from a previous Q&A session that was held with Ross he was saying that cost is primarily driven by the the number of sites because of all that goes into getting ethics approval, then initiation and training at each. Particularly with a short treatment trial such as this (though he was talking about MEND at the time). The cost isn't really driven by number of patients unless you have extremely high product costs. The patient being treated in the hospital would be there anyway, as would the doctors, nurses, orderlies etc. Those aren't costs of the trial, they're already there in the health system. The incremental trial costs in the hospital are provision of product and data recording so additional patients treated at the same site are generally very low cost.

That's the trade off they have to weigh up in conducting a trial - opening up additional sites to speed up recruitment (if that's slow) will blow out the cost.

Expand

The other MSC company has received FDA success for ALL P2 trials they conducted. Stellar results.

They did each of them economically and successfully. That’s not my opinion, it’s historical fact.

CYP Price at posting: 19.0¢ Sentiment: None Disclosure: Not Held
Upvote

0 Great analysis

Reply

Top Stories

PL3

Patagonia looks to raise $2.15M for South American exploration and development

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

There are more pages in this discussion • 50 more messages in this thread...

First 2079 Last

Add CYP (ASX) to my watchlist

(20min delay)
Last 25.0¢		Change 0.000(0.00%)		Mkt cap ! $44.90M

Open	High	Low	Value	Volume
25.5¢	26.0¢	24.5¢	$19.72K	78.84K

Buyers (Bids)

No.	Vol.	Price($)
2	31298	24.5¢

Sellers (Offers)

Price($)	Vol.	No.
25.0¢	39430	1

View Market Depth

No.	Vol.	Price($)
2	31298	0.245
4	112215	0.240
2	119148	0.235
2	15173	0.230
1	20000	0.225

Price($)	Vol.	No.
0.250	39430	1
0.260	25384	1
0.290	1900	1
0.295	183892	1
0.300	85000	2

Last trade - 15.59pm 09/07/2024 (20 minute delay)

CYP (ASX) Chart

Going forward..., page-2079

Patagonia looks to raise $2.15M for South American exploration and development

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Going forward..., page-2079

Top Stories

Patagonia looks to raise $2.15M for South American exploration and development

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News